S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:AKYA

Akoya Biosciences (AKYA) Stock Price, News & Analysis

$3.80
-0.05 (-1.30%)
(As of 04/19/2024 ET)
Today's Range
$3.77
$3.97
50-Day Range
$3.80
$6.03
52-Week Range
$3.04
$8.80
Volume
172,141 shs
Average Volume
153,505 shs
Market Capitalization
$186.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.07

Akoya Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
138.7% Upside
$9.07 Price Target
Short Interest
Healthy
4.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.22mentions of Akoya Biosciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$74,325 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.86) to ($0.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.97 out of 5 stars

Medical Sector

361st out of 909 stocks

Analytical Instruments Industry

13th out of 26 stocks

AKYA stock logo

About Akoya Biosciences Stock (NASDAQ:AKYA)

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

AKYA Stock Price History

AKYA Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)
Akoya Biosciences CEO sells $37k worth of shares
Akoya Biosciences Inc (AKYA)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Q4 2023 Akoya Biosciences Inc Earnings Call
Recap: Akoya Biosciences Q4 Earnings
Akoya Biosciences earnings: here's what to expect
Earnings Outlook For Akoya Biosciences
RNA Mar 2024 12.500 put
See More Headlines
Receive AKYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
4/20/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AKYA
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.07
High Stock Price Target
$11.00
Low Stock Price Target
$7.50
Potential Upside/Downside
+138.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-63,320,000.00
Pretax Margin
-65.49%

Debt

Sales & Book Value

Annual Sales
$96.63 million
Book Value
$1.10 per share

Miscellaneous

Free Float
44,964,000
Market Cap
$186.73 million
Optionable
Optionable
Beta
1.48
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Brian McKelligon (Age 55)
    President, CEO & Director
    Comp: $1.15M
  • Mr. John Frederick Ek (Age 48)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Frederic G. Pla Ph.D. (Age 65)
    Chief Operating Officer
    Comp: $445.27k
  • Priyam Shah
    Senior Director of Business Development & Investor Relations Strategy
  • Ms. Jennifer Kamocsay (Age 53)
    General Counsel
  • Dr. Niro Ramachandran Ph.D. (Age 49)
    Chief Business Officer
    Comp: $298.18k
  • Dr. Pascal Bamford Ph.D.
    Senior Vice President, Research & Development and Laboratory Operations
  • Mr. Rob C. Hart CFA
    J.D., Secretary

AKYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Akoya Biosciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AKYA shares.
View AKYA analyst ratings
or view top-rated stocks.

What is Akoya Biosciences' stock price target for 2024?

7 Wall Street analysts have issued 1-year price objectives for Akoya Biosciences' stock. Their AKYA share price targets range from $7.50 to $11.00. On average, they anticipate the company's share price to reach $9.07 in the next year. This suggests a possible upside of 138.7% from the stock's current price.
View analysts price targets for AKYA
or view top-rated stocks among Wall Street analysts.

How have AKYA shares performed in 2024?

Akoya Biosciences' stock was trading at $4.88 at the beginning of 2024. Since then, AKYA stock has decreased by 22.1% and is now trading at $3.80.
View the best growth stocks for 2024 here
.

Are investors shorting Akoya Biosciences?

Akoya Biosciences saw a drop in short interest in March. As of March 31st, there was short interest totaling 988,400 shares, a drop of 5.9% from the March 15th total of 1,050,000 shares. Based on an average daily trading volume, of 203,800 shares, the short-interest ratio is presently 4.8 days. Approximately 4.7% of the shares of the stock are short sold.
View Akoya Biosciences' Short Interest
.

When is Akoya Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AKYA earnings forecast
.

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) announced its quarterly earnings results on Monday, March, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.05. The company had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.12 million. Akoya Biosciences had a negative net margin of 65.53% and a negative trailing twelve-month return on equity of 110.24%. During the same quarter last year, the company posted ($0.50) EPS.

What guidance has Akoya Biosciences issued on next quarter's earnings?

Akoya Biosciences updated its FY 2024 earnings guidance on Monday, March, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $114.0 million-$118.0 million, compared to the consensus revenue estimate of $117.4 million.

When did Akoya Biosciences IPO?

Akoya Biosciences (AKYA) raised $125 million in an initial public offering on Friday, April 16th 2021. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as the underwriters for the IPO.

How do I buy shares of Akoya Biosciences?

Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKYA) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners